Biophan Forms Scientific Advisory Board for MYOTECH; Top Cardiologist and Cardio-Thoracic Surgeons Join Advisory Board to Support Development of the MYO-VAD(TM) Cardiac Assist Device.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, today announced the formation of a Scientific Advisory Board to oversee the development, clinical evaluation, and commercialization of MYO-VAD, a novel cardiac assist device designed to treat many types of heart failure. Biophan Technologies, Inc. holds a 42% interest in MYOTECH with rights to acquire a majority position, and is leading MYOTECH's business development activities.

The Scientific Advisory Board comprises the following individuals:

Mark P. Anstadt, MD, FACS is Associate Professor of Cardiothoracic Surgery at Wright State University of Medicine and Associate Medical Director of Miami Valley Heart and Lung Inc., both in Dayton, OH. He is also co-inventor of the MYO-VAD device. Dr. Anstadt will serve as Chairman of the Scientific Advisory Board.

James Lowe, MD is Professor of Cardiac Surgery and Professor of Pathology at Duke University Medical Center (DUMC). His research and clinical interests include non-blood-contacting biventricular mechanical support. Dr. Lowe pioneered early and successful application of the MYO-VAD technology in humans at DUMC under Early/Expanded Access criteria.

Douglas A. Mann, MD, FACC, FACP is Professor of Medicine and Molecular Physiology and Biophysics at Baylor School of Medicine and Director of the Winters Center for Heart Failure Research. Dr. Mann is actively involved in many aspects of addressing heart failure, including molecular mechanisms through assessment and treatment, implantable devices, drug therapy, and emerging strategies.

Carmelo Milano, MD is Associate Professor of Surgery at Duke University in the Division of Thoracic and Cardiovascular Surgery, and is Surgical Director of Cardiac Transplantation and LVAD Programs. Dr. Milano's research and clinical interests include gene therapy approaches to cardiovascular diseases and surgical treatments for heart failure. Dr. Milano also helped to pioneer early application of the technology in humans at Duke.

Benjamin Sun, MD is Associate Professor of Surgery, Chief, Division of Cardiothoracic Surgery, and Director of Cardiac Transplantation and Mechanical Support at Ohio State University Medical Center. Dr. Sun's research interests include development of chronic heart failure models supported by mechanical support. He is a recognized leader in the field of mechanical circulatory support, and lectures worldwide.

"Each of these distinguished physicians and scientists are leaders in the field of heart failure and cardiac support," said Jeffrey Helfer, MYOTECH's CEO and President of Biophan's Cardio-Vascular division. "We are honored that they have agreed to serve as members of MYOTECH's Scientific Advisory Board. The new advisory board's expertise will be an invaluable resource in developing and commercializing the MYO-VAD," added Mr. Helfer.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems that the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies that will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices, such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI.

The Company is helping to commercialize the MYO-VAD, a novel, MRI-compatible cardiac assist device, which has the potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems that derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of over 200 U.S. and international patents, licenses, or applications. This includes 56 issued U.S. patents and over 100 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.

About MYOTECH, LLC 

MYOTECH, LLC, is a privately held medical technology development company, formed in 2003 to commercialize a family of medical products based upon Direct Mechanical Ventricular Actuation ("DMVA") cardiac assist technology. This technology has permitted the development of cardiac assist products that promise to provide safer, more effective, and less expensive treatment for patients with many types of acute and chronic heart failure conditions. MYOTECH's products do not contact circulating blood, a major cause of the clotting and stroke, bleeding, and infection complications of today's cardiac assist devices. The Company has relationships with leading physicians and medical institutions who are actively engaged in the development and clinical evaluation of the technology. MYOTECH has several pending patents pertaining to the DMVA technology, including cardiac-directed drug delivery, gene and stem cell therapy, and full device implantability.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.